Q-omics provides the consensus-scored DHRS7B profile across patient tissues and cancer cell-line models. DHRS7B expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, DHRS7B is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, DHRS7B protein abundance shows 21,954 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight UVM, KICH, and PDAC as cancer lineages where DHRS7B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DHRS7B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DHRS7B survival associations across molecular data types. DHRS7B RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DHRS7B RNA expression–survival associations across cancer types. High DHRS7B expression shows unfavorable associations in UVM and LGG, but favorable associations in UCEC, STAD, MESO and KIRP. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for DHRS7B RNA expression.
This table summarizes DHRS7B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in KICH for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for DHRS7B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DHRS7B shows lower tumor expression in KICH, LUSC, THCA, LUAD and BRCA and higher tumor expression in LIHC. The KICH box plot shows higher DHRS7B RNA expression in normal versus tumor tissue (log2 FC = −1.554, t-test p < 0.001).
This table shows molecular features associated with DHRS7B in patient tissues and cancer cell lines. In patient samples, DHRS7B shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, DHRS7B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and SOFT_TISSUE.
